ERG and Familial prostate cancer: We characterized AR, MYC, and TMRPSS2-ERG expression in two established primary prostate cancer xenograft models: the castration-resistant LuCaP 35CR model (formerly named LuCaP 35V; [21]) and the neuroendocrine prostate cancer model LuCaP 145.2.